Evidence map›Paper›PMID 32481659›Full record

ArticleInternational journal of molecular sciences2020

Role of

Rina Fujiwara-Tani, Kiyomu Fujii, Shiori Mori, Shingo Kishi, Takamitsu Sasaki, Hitoshi Ohmori, Chie Nakashima, Isao Kawahara, Yukiko Nishiguchi, Takuya Mori and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Claudin-4: A New Molecular Target for Epithelial Cancer Therapy.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Article
  13. Hypomethylation ofInternational journal of molecular sciences · 2022
    Article
  14. Article
  15. Targeting claudins in cancer: diagnosis, prognosis and therapy.American journal of cancer research · 2021
    Review
  16. Review
  17. Role of Nuclear Claudin-4 in Renal Cell Carcinoma.International journal of molecular sciences · 2020
    Article
  18. Immunoexpression of Claudins -3, -4 and -7 in prostate adenocarcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Rina Fujiwara-TaniDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Kiyomu FujiiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Shiori MoriDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Shingo KishiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Chie NakashimaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Isao KawaharaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Yukiko NishiguchiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Takuya MoriDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Masayuki ShoDepartment of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Masuo KondohDrug Innovation Center, Graduate School of Pharmaceutical Sciences, Osaka University, 6-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
Yi LuoKey Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province 226001, China.
Hiroki KuniyasuDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.ORCID 0000-0003-2298-8825
Nara Medical University · JPNantong University · CNThe University of Osaka · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 16H05164Ministry of Education, Culture, Sports, Science and Technology 17K19923Ministry of Education, Culture, Sports, Science and Technology 19K16564National Natural Science Foundation of China 81702723Natural Science Foundation of Jiangsu Education Department Project 17KJB320010
6 · The paper itself

Abstract

Sessile serrated adenoma/polyp with dysplasia (SSA/P-D) is an SSA/P with cellular dysplasia and has a higher risk of progressing to colon carcinogenesis. Previously, we reported that tight junction impairment by

Indexed as

Active Transport, Cell NucleusAdaptor Proteins, Signal TransducingAdenomaAnimalsApoptosis Regulatory ProteinsCadherinsCarcinogenesisCarcinoma, Squamous CellCell Line, TumorCell MembraneClaudin-4Clostridium perfringensColonic PolypsColorectal NeoplasmsCytoplasmDisease ProgressionAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCadherinsClaudin-4enterotoxin, ClostridiumEnterotoxinsTranscription FactorsYAP1 protein, humanYap1 protein, ratYAP-Signaling Proteinsclaudin-4clostridium perfringens enterotoxinHippo signalSSA/PYAP

Identifiers

PMID32481659
PMCPMC7313056
OpenAlexW3032477724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.